Oncology Episode Payment Model in Hawaii

March 11, 2024 updated by: Amol Navathe, University of Pennsylvania
The HMSA Cancer Episode Payment Model (CEM) is a payment model designed to test the effects of better care coordination on health outcomes and costs of care for Hawaii Medical Services Association (HMSA) members with cancer who receive chemotherapy.

Study Overview

Status

Active, not recruiting

Detailed Description

The CEM is designed to improve community health, to improve care coordination, quality, and appropriateness of care, to improve patient experience, and to implement a value-based incentive structure that appropriately rewards oncologists for cost-savings and sustained of improved quality of care.

Study Type

Interventional

Enrollment (Actual)

7

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Hawaii
      • Honolulu, Hawaii, United States, 96701
        • Hawaii Oncology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Any oncologist who practices with Hawaii Oncology and is a participating provider.

Exclusion Criteria:

  • Any provider who does not practice with Hawaii Oncology.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cancer Episode Payment Model
Oncologists in this arm will be paid for each member's episode of care. The episode of care is 6 months in duration. Oncologists will have the opportunity to receive performance-based payments based upon a set of 6 quality metrics.
Oncologists will be paid for an episode of care with the opportunity to receive a value based payment based on 6 quality metrics.
No Intervention: Fee for Service
Oncologists in this arm will not receive the intervention and will continue to be paid through fee-for-service.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Composite quality score
Time Frame: 1 year
Quality metrics included in the oncology model will be compared across the two arms.
1 year
Episode cost
Time Frame: 6 months
Total spending of oncology patients in the episode will be compared across the two arms.
6 months
Utilization of acute and specialty care
Time Frame: 6 months
Total utilization of acute and specialty care of oncology patients in the episode will be compared across the two arms
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quality of care at end of life
Time Frame: 6 months
Quality measures evaluating use of acute care and palliative care services at the end of life will be compared across the two arms
6 months
Survival
Time Frame: one year
All cause mortality will be compared across the two arms
one year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2018

Primary Completion (Estimated)

January 1, 2026

Study Completion (Estimated)

January 31, 2026

Study Registration Dates

First Submitted

April 19, 2018

First Submitted That Met QC Criteria

May 1, 2018

First Posted (Actual)

May 14, 2018

Study Record Updates

Last Update Posted (Actual)

March 13, 2024

Last Update Submitted That Met QC Criteria

March 11, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on Cancer Episode Payment Model (CEM)

3
Subscribe